Hazard | 95.0% CI for HR | p-value | |||
---|---|---|---|---|---|
ratio | Lower | Upper | |||
Diagnose origin | |||||
IPC | Reference | 1.00 | |||
OPC | 0.89 | 0.68 | 1.16 | 0.06 | |
Primary care | 0.52 | 0.35 | 0.77 | < 0.001 | |
Emergency department | 1.23 | 0.78 | 1.94 | 0.80 | |
Sex and age | |||||
Women | 0.88 | 0.72 | 1.07 | 0.20 | |
Age | 1.02 | 1.00 | 1.03 | 0.01 | |
Systolic blood pressure | |||||
< 100 mm Hg | Reference | 1.00 | |||
100–130 mmHg | 0.61 | 0.32 | 1.14 | 0.31 | |
> 130 mm Hg | 0.54 | 0.29 | 1.00 | 0.21 | |
Renal function | |||||
eGFR > 60 ml/min | Reference | 1.00 | |||
eGFR 30–60 ml/min | 0.87 | 0.69 | 1.09 | 0.30 | |
eGFR < 30 ml/min | 0.85 | 0.58 | 1.24 | 0.40 | |
Glucose regulation | |||||
HbA1c < 52 mmol/ml | Reference | 1.00 | |||
HbA1c 52–70 mmol/ml | 0.85 | 0.69 | 1.05 | 0.43 | |
HbA1c > 70 mmol/ml | 0.76 | 0.54 | 1.07 | 0.90 | |
LDL-cholesterol ≥ 2.5 mmol/ml | 1.00 | ||||
LDL-cholesterol < 2.5 mmol/ml | 1.05 | 0.84 | 1.32 | 0.67 | |
Pharmacotherapy | |||||
Insulin | 1.29 | 1.04 | 1.61 | 0.02 | |
Metformin | 0.88 | 0.70 | 1.10 | 0.25 | |
DPP4 | 1.38 | 1.10 | 1.74 | 0.006 | |
GLP1 | 1.04 | 0.78 | 1.38 | 0.81 | |
SGLT2 | 1.01 | 0.77 | 1.34 | 0.93 | |
Aldosterone antagonist | 1.63 | 1.27 | 2.08 | < 0.001 | |
Betablocker | 1.34 | 1.08 | 1.67 | 0.008 | |
Calcium blocker | 1.21 | 0.99 | 1.47 | 0.06 | |
RAASi | 1.01 | 0.80 | 1.26 | 0.95 | |
Statin | 0.97 | 0.71 | 1.32 | 0.82 | |
Healthcare utilization | |||||
Hospital out-patient care visit > 30 days | Reference | 1.00 | |||
Hospital out-patient care visit ≤ 30 days | 2.19 | 1.70 | 2.82 | < 0.001 | |
Primary care visit > 30 days | Reference | 1.00 | |||
Primary care visit ≤ 30 days | 0.86 | 0.70 | 1.05 | 0.13 |